Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (1) , 52-58
Abstract
Tissue-based multigene panel (genomic) tests have been developed and are commercially available for patients with several forms of cancer, including breast, melanoma, and prostate.1-4 Although a range of prognostic tests assess distinct cancer types and underlying pathways, they share a common goal of personalizing decision-making, often modifying the necessity or intensity of treatment based on an individual’s risk. These tests have been particularly promising for the management of prostate cancer, where the aggressiveness of the disease varies considerably among men with localized cancers.5 In retrospective studies, several multigene panels for prostate cancer have been shown to add independent prognostic information beyond standard clinical variables, such as prostate-specific antigen (PSA) level, Gleason score, or clinical stage.6 Although it has been assumed that genomic tests will enhance the precision with which the disease is managed (ie, increased active surveillance for nonaggressive cancers and timely treatment for those with aggressive disease), the effectiveness of testing has not been independently established.7-9 Nevertheless, genomic tests have recently become incorporated into major clinical practice guidelines, such as those from the National Comprehensive Cancer Network, and are covered by most major insurance carriers, including Medicare.Keywords
This publication has 39 references indexed in Scilit:
- Effect of a genomic classifier test on clinical practice decisions for patients with high‐risk prostate cancer after surgeryBJU International, 2014
- Regional Variation in Quality of Prostate Cancer CareJournal of Urology, 2014
- Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancerCurrent Medical Research and Opinion, 2013
- Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate CancerJAMA, 2013
- Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate CancerJournal of Clinical Oncology, 2011
- The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy RatesMedical Care, 2011
- Group-Based Trajectory Modeling in Clinical ResearchAnnual Review of Clinical Psychology, 2010
- Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular MarkersThe American Statistician, 2008
- Delay of Radical Prostatectomy and Risk of Biochemical Progression in Men With Low Risk Prostate CancerJournal of Urology, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004